IND/IDE Support

The IND/IDE Specialist is responsible for developing, coordinating, and implementing research strategies essential to the successful management of Investigational New Drug (IND) and Investigational Device Exemption (IDE) applications for Phase I, II, III, and/or IV clinical trials.

The IND/IDE Specialist provides high-level expertise, guidance, and support to investigators, reviewing, developing, and submitting applications to the FDA to support sponsor-investigator INDs and IDEs, including the following:

  • Pre-INDs and pre-submission meetings
  • Initial INDs and IDE submissions
  • Amendments
  • Supplements
  • Safety reporting
  • Annual reports

The IND/IDE Specialist also provides support to sponsor-investigators and study teams in the development of FDA submissions and reviews essential documents such as initial and amended protocols and FDA required forms.

Other essential functions of this role include:

  • Develop IND/IDE related policies, procedures, and templates
  • Develop and report on program performance metrics
  • Maintain master IND and IDE files
  • Assist with internal and external QA audits
  • Participate in required IND/IDE meetings and workshops

Serve as a liaison with the FDA as necessary

Frequently Asked Questions

  1. What is a Clinical Investigation?
  2. Who is the Sponsor of an IND or IDE Application?
  3. What are the Responsibilities of an IND or IDE Holder?
  4. What Is An IND Application?
  5. What Is An IDE?
  6. When Do You Need An IND?
  7. When Do You Need An IDE?
  8. What If Your Device Study is Exempt from IDE Requirements?
  9. What to do for Assistance in Submitting an IND to FDA?
  10. IND Submission Services?
  11. IDE Submission Services?
  12. How to Monitor Your Study?

1. What is a Clinical Investigation?

The FDA defines a clinical investigation is an experiment in which a drug is “administered or dispensed to, or used involving, one or more human subjects. Such an experiment is any use of a drug [whether approved or unapproved] except for the use of a marketed drug in the course of medical practice." In order to conduct a clinical investigation of a drug, biologic, or device an IND or IDE application must be filed with the FDA, unless the study is exempt from IND or IDE requirements.

2. Who is the Sponsor of an IND or IDE Application?

The sponsor is the party who submits the application to FDA. In the absence of any other sponsor (e.g. pharmaceutical company or government agency), the investigator conducting the proposed clinical investigation is the sponsor of the IND or IDE application.

3. What are the Responsibilities of an IND or IDE Holder?

The holder of an IND or IDE initiates and actually conducts, alone or with others, a clinical investigation, and the investigational drug or device is administered, dispensed, or used under his or her immediate direction. He or she assumes the responsibilities of both an investigator and a sponsor when all of the following are true:

  1. The sponsor investigator obtained an IND or IDE from FDA
  2. The sponsor investigator is responsible for clinical testing of the drug or device
  3. The sponsor investigator is conducting a clinical trial and dispensing or using the drug or device in human subjects.

Back to Top

4. What Is An IND Application?

An Investigational New Drug (IND) application is submitted to the FDA if a drug (or biological product) not previously authorized for marketing in the US is intended to be used for the purposes of clinical investigation or, in certain cases, for the purposes of clinical treatment when no approved therapies are available.

5. What Is An IDE?

An Investigational Device Exemption (IDE) application is submitted to the FDA to allow for the conduct of a clinical investigation using a significant risk device that is new or not approved for a given use.

6. When Do You Need An IND?

An IND is required when all of the following conditions exist (21CFR 312):

  • The research involves a drug as that term is defined in section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 321(g)(1)).
  • The research is a clinical investigation as defined in the IND regulations (21 CFR 312.3).
  • The clinical investigation is not otherwise exempt from the IND requirements in part 312 (see section IV of this guidance).

Whether an IND is needed to conduct a clinical investigation of a marketed drug primarily depends on the intent of the investigation and the degree of risk associated with the use of the drug in the investigation. A clinical investigation of a marketed drug is exempt from the IND requirements if all of the criteria for an exemption in § 312.2(b) are met:

  • The drug product is lawfully marketed in the United States.
  • The investigation is not intended to be reported to FDA as a well-controlled study in support of a new indication and there is no intent to use it to support any other significant change in the labeling of the drug.
  • In the case of a prescription drug, the investigation is not intended to support a significant change in the advertising for the drug.
  • The investigation does not involve a route of administration, dose, patient population, or other factor that significantly increases the risk (or decreases the acceptability of the risk) associated with the use of the drug product (21 CFR 312.2(b)(1)(iii)).
  • The investigation is conducted in compliance with the requirements for review by an IRB (21 CFR part 56) and with the requirements for informed consent (21 CFR part 50).
  • The investigation is conducted in compliance with the requirements of § 312.7 (i.e., the investigation is not intended to promote or commercialize the drug product).

Additionally, when an IND is required, the study must be conducted in compliance with 21 CFR 312.7, which deals with the promotion and sale of investigational products.

IND exempt studies must comply with informed consent and IRB approval requirements (21 CFR 50 and 56, respectively). If a study does not require an IND per the FDA, the investigator must be able to document this determination, and the Institutional Review Board (IRB) will verify documentation.

Back to Top

7. When Do You Need An IDE?

Significant vs. Non-significant Risk Devices

An IDE is required to study an investigational device (including new intended use of an approved device) posing significant risk (presents a potential serious risk to the health, safety, or welfare of subjects) and must be submitted to the FDA before study initiation. If the investigation involves the use of a device that does not pose significant risk to humans (a non-significant risk device), an IDE application to FDA is not required. Submissions for non-significant risk devices are made directly to the IRB. The sponsor-investigator must explain to the IRB why the device does not pose a significant risk. If the IRB agrees with the non-significant risk determination, the FDA considers the device to have an approved IDE. However, if the IRB determines that the device poses a significant risk to subjects, the sponsor-investigator must notify the FDA within five working days. Sponsor-investigators conducting non-significant risk device studies must comply with IDE requirements listed in 21 CFR 812.2(b).

8. What If Your Device Study is Exempt from IDE Requirements?

While an approved IDE allows investigators to use an investigational device for the purpose of clinical testing, not all clinical trials using devices require permission from the FDA to proceed. Device studies exempt from IDE requirements still require IRB approval (21 CFR 56). Documentation of the IDE exemption category must be submitted to IRB.

The following categories of devices are exempt from IDE requirements:

  • Devices in commercial distribution before 5/28/1976
  • Devices determined by FDA to be substantially equivalent to a device in commercial distribution before 5/28/1976
  • Diagnostic devices that are noninvasive or do not require an invasive sampling procedure that presents significant risk, do not introduce energy into a subject or are not used as a diagnostic procedure without the confirmation of another medically established diagnostic product or procedure
  • Devices used for consumer preference testing or for any test that is not intended to determine safety or effectiveness and does not expose subjects to risk
  • Devices exclusively used for veterinary indications
  • Devices to be shipped exclusively for research on laboratory animals
  • Custom devices unless these are used to assess safety or effectiveness for commercial distribution

Back to Top

9. What to do for Assistance in Submitting an IND to FDA?

For advice on IND or IDE submission requirements or exemptions, and for assistance in the preparation and submission of an IND or IDE, contact:

Jonna Montgomery
295 S Chipeta Way 1S100
Salt Lake City, UT 84108
Office: 801-587-0976

jonna.montgomery@hsc.utah.edu

10. IND Submission Services?

Pre IND Meeting Process – Meeting Request and Background Preparation, Submission, and FDA Coordination

IND Sponsor Investigators can learn about the soundness of study design and study acceptability from a Pre-IND consultation with the FDA. Through the Pre-IND consultation program, potential IND holders can consult with the FDA to discuss preclinical studies needed to support clinical testing, understand study product chemistry, manufacturing and control (CMC) issues, and to preview the proposed clinical study.

Initial IND Application – Application Preparation, Submission, and FDA Coordination

Required information includes:

  • Complete protocol and study documents
  • Informed consent form
  • List of all investigators and sub-investigators and a Curriculum Vitae for each investigator listed
  • List of all study locations
  • List of all clinical laboratories
  • Study drug Investigator Brochure, or product package insert
  • Pharmacy Manual (if applicable)
  • Response to FDA PIND comments
  • Letter authorizing IND or NDA cross reference for study drug ( if applicable)
  • Principal Investigator signature on FDA regulatory forms and cover letter

Address Post IND Requirements

Internal and external audit assistance
Coordinate Communication
Amendment preparation and submission
Adverse event reporting
Annual Report preparation and submission
File Study Completion or Termination

Back to Top

11. IDE Submission Services?

Pre Sub Meeting Process – Pre Sub Meeting Preparation, Submission, and FDA Coordination

IDE Sponsor Investigators can utilize early communication with the Office of Device Evaluation

(ODE) through an IDE Pre Sub meeting, which is a valuable resource for sponsor investigators and studies with new technology. This meeting increases the understanding of FDA requirements for IDE studies and applications and decreases delays in the submission process.

Initial IDE Application – Application Preparation, Submission, and FDA Coordination

Required information includes:

  • Statement that the information provided is an original IDE submission.
  • Device Information:
    • Device Name
    • Intended Use
    • Thorough description of medical device
  • Sponsor contact information
  • Manufacturer Information
  • Complete protocol and study documents
  • Informed consent form
  • Pre-Submission meeting information and response to FDA comments.
  • Principal Investigator signature on FDA regulatory forms and cover letter

Address Post IDE Requirements

Response to FDA IDE Conditions
Internal and external audit assistance
Coordinate Communication
Amendment preparation and submission
Adverse event reporting
Annual Report preparation and submission
File Study Completion or Termination

Back to Top

12. How to Monitor Your Study?

Sponsor Investigators are required to ensure regulatory compliance with FDA requirements, the protocol, IRB requirements, and all applicable regulations. IND/IDE holders must ensure that all federal, state and institutional regulations are being met.

Monitoring & Quality Assurance

LEADERSHIP

J. Michael Dean

J. Michael Dean, MD, MBA

Associate Dean for Clinical Research
Professor 
Vice Chairman for Research
Deptartment of Pediatrics
Director, Clinical Trials Office
Chief, Division of Pediatric Critical Care
University of Utah School of Medicine

Jaci Skidmore

Director, Clinical Research Operations

CONTACT US 

Phone: 801-587-7514
Email: jaci.skidmore@hsc.utah.edu

UPCOMING EVENTS

Research Professionals Grand Rounds

For more information, contact:
Jaci Skidmore
jaci.skidmore@hsc.utah.edu